NCT07046936
Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer
Recruiting
Not specifiedAges 50+ObservationalWake Forest University Health SciencesInvestigator-initiated
~30 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:muscle sampleblood draw
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Screening rate
Measured over Screening
+3 more outcomes measured
Conditions
Where it's being run
2 sites across 1 statesNorth Carolina2
Study leadership
- Bumsoo Ahn, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Ability to understand and willingness to sign an IRB-approved informed consent
Age ≥50 years at the time of enrollment
Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype
Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy OR tumor reduction surgery with adjuvant chemotherapy
Ability to read and understand the English language
Exclusion
Previously treated for ovarian or endometrial cancer
History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia
Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator
Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study
What this trial measures
- Screening rateScreening
Proportion of approached patients who signed consent out of the total number of patients who were approached
- Enrollment rateScreening and pretreatment
Proportion of consented participants who initiated at least one pretreatment assessment or had pretreatment blood drawn out of the total number of consented participants
- Completion ratePretreatment and up to 30 days following the completion of adjuvant chemotherapy.
Proportion of enrolled participants who completed at least one posttreatment assessment (cognitive or physical) out of the total number of enrolled participants
- Study FeasibilityScreening and up to 30 days following the completion of adjuvant chemotherapy
≥80% enrollment rate, ≥80% completion rate (30 of 37)